( NASDAQ-SMALL:IMNP )

News from Immune Pharmaceuticals Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 17, 2017, 09:15 ET Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia

Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany...


Jan 27, 2017, 07:00 ET Immune Pharmaceuticals Appoints New Chairman of the Board of Directors

Immune Pharmaceuticals Inc. (Nasdaq: IMNP), announced today it has appointed Ranch C. Kimball, a highly regarded executive in healthcare,...


Jan 23, 2017, 08:45 ET Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company developing novel therapeutics for the...


Jan 17, 2017, 09:10 ET Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI

Immune Pharmaceuticals (NASDAQ: IMNP) ("Immune"), a clinical stage biopharmaceutical company, announced today that it will hold a Satellite...


Jan 09, 2017, 18:11 ET Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq's Minimum Bid Price Rule

Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune"), announced today that it intends to request a hearing before the Nasdaq Listing...


Nov 22, 2016, 09:00 ET Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016

Immune Pharmaceuticals (NASDAQ: IMNP) (Immune) announced today that it will hold an Immuno-Oncology R&D Update for investors on December 8,...


Nov 17, 2016, 09:15 ET Immune Pharmaceuticals Secures Up to $11 Million in New Financing to be Deployed With a Focus on Bertilimumab Clinical Development

Immune Pharmaceuticals (NASDAQ:IMNP) (Immune) announced today that it has secured up to $11 million in new financing from a single family office...


Oct 27, 2016, 07:00 ET Immune Pharmaceuticals Receives FDA Guidance for Phase III Pivotal Trial of its AML Therapy Ceplene® In Combination with Low Dose IL-2

Immune Pharmaceuticals (NASDAQ:IMNP) (Immune) announced today that it has received guidance from the United States Food and Drug Administration...


Oct 17, 2016, 09:23 ET Immune Pharmaceuticals Announces Formation of Management Team for Maxim Pharmaceuticals, its Pain and Neurology Subsidiary

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a consulting agreement with Joseph V. Pergolizzi...


Sep 16, 2016, 07:30 ET Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company"), a biopharmaceutical company focused on the development of targeted...


Sep 07, 2016, 07:30 ET Immune Pharmaceuticals Receives $2 Million Investment in Common Stock at $0.50 per Share

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the...


Aug 16, 2016, 07:30 ET Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results

 Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") announced financial results for the second quarter and six months ended...


Jul 19, 2016, 09:30 ET IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet

Immune Pharmaceuticals Inc. (NASDAQ: IMNP)("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the...


Jun 28, 2016, 07:00 ET New Data Suggests Improved Tumor Response For The Combination of AZIXA® and Immune Checkpoint Inhibitors in The Treatment of Cancer

 Immune Pharmaceuticals Inc. ("Immune" or the "Company") (NASDAQ: IMNP), a clinical-stage biopharmaceutical company announced today that recent...


Jun 20, 2016, 17:30 ET New Data shows that Ceplene® Enhances Response to anti PD-1 and anti-PD-L1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models

 Immune Pharmaceuticals (NASDAQ:IMNP),("Immune"),  a clinical stage biopharmaceutical company announced that  scientists from...


Jun 20, 2016, 08:06 ET Immune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company announced today that Dr. Daniel Teper,...


Jun 14, 2016, 07:30 ET Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune"), a biopharmaceutical company focused on the development of targeted therapeutics for the...


Jun 07, 2016, 19:56 ET Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases

Immune Pharmaceuticals Inc. ("Immune"), a biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of...


May 16, 2016, 07:30 ET Immune Pharmaceuticals Provides Business and R&D Update and Announces First Quarter 2016 Financial Results

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced financial results for the first quarter ended March 31, 2016....


Mar 30, 2016, 18:41 ET Immune Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Full Year 2015 Financial Results

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced financial results for the fourth quarter and full year ended...


Mar 22, 2016, 07:30 ET Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), ("Immune"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...


Mar 17, 2016, 07:30 ET New Data on Ceplene® Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that new clinical pharmacology and outcomes data with Ceplene (histamine...


Feb 29, 2016, 07:30 ET Immune Pharmaceuticals and The International Pemphigus & Pemphigoid Foundation (IPPF) Celebrate Rare Disease Day

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, and the International Pemphigus &...


Feb 25, 2016, 07:30 ET Immune Pharmaceuticals Names Dr. Jeff Paley to its Board of Directors

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, announced today that it has...


Feb 24, 2016, 07:30 ET Immune Pharmaceuticals Announces Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, announces publication of new data on the role of...